These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25667568)

  • 1. cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.
    Chi J; Pierides C; Mitsidou A; Miltiadou A; Gerasimou P; Costeas P
    Biol Proced Online; 2015; 17(1):4. PubMed ID: 25667568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
    PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse Transcription Can Critically Impact the Diagnostic Outcome of
    Spiess B; Kleiner H; Tarnopolscaia I; Naumann N; Fabarius A; Hofmann WK; Saussele S; Seifarth W
    Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M; Whale AS; Akiki S; Piechocki K; Torrado C; Myint T; Cowen S; Griffiths M; Reid AG; Apperley J; White H; Huggett JF; Foroni L
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH; Li H; Cai H
    Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.
    Alikian M; Gale RP; Apperley JF; Foroni L
    Biomol Detect Quantif; 2017 Mar; 11():4-20. PubMed ID: 28331814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
    Ross DM; Watkins DB; Hughes TP; Branford S
    Clin Chem; 2008 Sep; 54(9):1568-71. PubMed ID: 18641042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ; Zheng CF; Liu Z; Tan YH; Chen XH; Zhao BL; Li GX; Xu ZF; Ren FG; Zhang YF; Chang JM; Wang HW
    Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances.
    Cumbo C; Anelli L; Specchia G; Albano F
    Cancer Manag Res; 2020; 12():3175-3189. PubMed ID: 32440215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for "personalized monitoring" of residual disease in chronic myeloid leukemia patients.
    Cumbo C; Impera L; Minervini CF; Orsini P; Anelli L; Zagaria A; Coccaro N; Tota G; Minervini A; Casieri P; Brunetti C; Rossi AR; Parciante E; Specchia G; Albano F
    Oncotarget; 2018 Feb; 9(13):10978-10986. PubMed ID: 29541390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.
    Pfeifer H; Cazzaniga G; van der Velden VHJ; Cayuela JM; Schäfer B; Spinelli O; Akiki S; Avigad S; Bendit I; Borg K; Cavé H; Elia L; Reshmi SC; Gerrard G; Hayette S; Hermanson M; Juh A; Jurcek T; Chillón MC; Homburg C; Martinelli G; Kairisto V; Lange T; Lion T; Mueller MC; Pane F; Rai L; Damm-Welk C; Sacha T; Schnittger S; Touloumenidou T; Valerhaugen H; Vandenberghe P; Zuna J; Serve H; Herrmann E; Markovic S; Dongen JJMV; Ottmann OG
    Leukemia; 2019 Aug; 33(8):1910-1922. PubMed ID: 30858550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of two commercially available BCR-ABL1 quantification assays that use an international reporting scale.
    Seo SH; Lee SJ; Park S; Kim MJ; Song JY; Ra EK; Cho SI; Kim HK; Yang MG; Kim JY; Park SS; Seong MW
    Clin Chem Lab Med; 2016 Jul; 54(7):1157-60. PubMed ID: 26587743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
    Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
    Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 and CD66c exhibit high concordance in minimal residual disease detection of adult B-acute lymphoblastic leukemia.
    Tang GS; Wu J; Liu M; Chen H; Gong SG; Yang JM; Hu XX; Wang JM
    Am J Transl Res; 2015; 7(3):632-9. PubMed ID: 26045902
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Pagani IS; Dang P; Kommers IO; Goyne JM; Nicola M; Saunders VA; Braley J; White DL; Yeung DT; Branford S; Hughes TP; Ross DM
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.
    Yoshida C; Nakamae H; Fletcher L; Koga D; Sogabe T; Matsumura I; Kanakura Y; Branford S; Naoe T
    Springerplus; 2016; 5():569. PubMed ID: 27247866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.
    Spiess B; Rinaldetti S; Naumann N; Galuschek N; Kossak-Roth U; Wuchter P; Tarnopolscaia I; Rose D; Voskanyan A; Fabarius A; Hofmann WK; Saußele S; Seifarth W
    PLoS One; 2019; 14(3):e0214305. PubMed ID: 30897165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of molecular responses based on BCR-ABL1% (IS) results from an in-house TaqMan-based qPCR versus Xpert(®) assay in CML patients on tyrosine kinase inhibitor therapy.
    Boeckx N; Laer CV; Roover JD; Wilmsen B; Bruyninckx K; Pauwels S
    Acta Clin Belg; 2015 Aug; 70(4):237-43. PubMed ID: 26166681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.